Item 2.02 Results of Operations and Financial Condition. On May 13, 2026, Tango Therapeutics, Inc. (“ Tango” or the “ Company”) issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Resignation of Alexis Borisy On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “ Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “ Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026. Mr. Borisy’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies. Resignation of Kanishka Pothula Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “ NCG Committee”), in each case effective as of May 13, 2026. Mr. Pothula’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies. In connection with Mr. Borisy’s and Mr. Pothula’s resignations from the Board, the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026. The Compensation Committee now consists of Sung Lee, John Ketchum and Mace Rothenberg, M. D. The Board also approved the appointment of Sung Lee as a member of the NCG Committee, effective as of May 13, 2026. The NCG Committee now consists of Mace Rothenberg, Sung Lee and Lesley Ann Calhoun.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Tango Therapeutics, Inc. on May 13, 2026 relating to its results of operations and financial condition for the quarter ended March 31, 2026. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TANGO THERAPEUTICS, INC. Dated: May 13, 2026 By: /s/ Matthew Gall Name: Matthew Gall Title: Chief Financial Officer